Jeffrey Leflein

979 total citations
16 papers, 250 citations indexed

About

Jeffrey Leflein is a scholar working on Physiology, Pulmonary and Respiratory Medicine and Rheumatology. According to data from OpenAlex, Jeffrey Leflein has authored 16 papers receiving a total of 250 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Physiology, 11 papers in Pulmonary and Respiratory Medicine and 3 papers in Rheumatology. Recurrent topics in Jeffrey Leflein's work include Asthma and respiratory diseases (13 papers), Inhalation and Respiratory Drug Delivery (10 papers) and Respiratory and Cough-Related Research (7 papers). Jeffrey Leflein is often cited by papers focused on Asthma and respiratory diseases (13 papers), Inhalation and Respiratory Drug Delivery (10 papers) and Respiratory and Cough-Related Research (7 papers). Jeffrey Leflein collaborates with scholars based in United States, Germany and Denmark. Jeffrey Leflein's co-authors include Mario Cruz‐Rivera, Sherahe Fitzpatrick, Joseph A. Smith, Torben Lildholdt, Mats R. Andersson, Anders Åkerlund, Naja Dam Mygind, Stanley J. Szefler, Karen Walton–Bowen and Christopher J. Miller and has published in prestigious journals such as American Journal of Respiratory and Critical Care Medicine, PEDIATRICS and Journal of Allergy and Clinical Immunology.

In The Last Decade

Jeffrey Leflein

15 papers receiving 232 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jeffrey Leflein United States 8 192 149 83 31 24 16 250
María Angeles Zambonino Spain 7 155 0.8× 49 0.3× 150 1.8× 9 0.3× 111 4.6× 12 355
R. Ferrenq Dubost France 5 177 0.9× 76 0.5× 197 2.4× 5 0.2× 115 4.8× 8 253
Andrea Di Rienzo Businco Italy 11 327 1.7× 52 0.3× 399 4.8× 17 0.5× 187 7.8× 13 455
M. L. Kowalski Poland 4 61 0.3× 32 0.2× 44 0.5× 3 0.1× 22 0.9× 6 151
Claudia Calogero Italy 8 113 0.6× 146 1.0× 41 0.5× 1 0.0× 51 2.1× 13 251
M. Lecasble France 6 226 1.2× 69 0.5× 236 2.8× 73 2.4× 47 2.0× 6 310
A Capristo Italy 8 197 1.0× 153 1.0× 81 1.0× 50 2.1× 10 246
Seçil Kepil Özdemir Türkiye 10 77 0.4× 44 0.3× 63 0.8× 2 0.1× 59 2.5× 22 227
Chien‐Chia Chuang United States 10 145 0.8× 17 0.1× 219 2.6× 9 0.3× 118 4.9× 25 335
Ayşegül Akan Türkiye 11 120 0.6× 64 0.4× 134 1.6× 110 4.6× 18 305

Countries citing papers authored by Jeffrey Leflein

Since Specialization
Citations

This map shows the geographic impact of Jeffrey Leflein's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeffrey Leflein with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeffrey Leflein more than expected).

Fields of papers citing papers by Jeffrey Leflein

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jeffrey Leflein. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeffrey Leflein. The network helps show where Jeffrey Leflein may publish in the future.

Co-authorship network of co-authors of Jeffrey Leflein

This figure shows the co-authorship network connecting the top 25 collaborators of Jeffrey Leflein. A scholar is included among the top collaborators of Jeffrey Leflein based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeffrey Leflein. Jeffrey Leflein is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Maurer, Marcus, Martin Metz, Iwona Kobielusz‐Gembala, et al.. (2025). Barzolvolimab Improves Urticaria Control and Quality of Life in Patients with Chronic Spontaneous Urticaria: 52-Week Data. Journal of Allergy and Clinical Immunology. 155(2). AB431–AB431. 1 indexed citations
2.
Maurer, Marcus, Iwona Kobielusz‐Gembala, Essack Mitha, et al.. (2024). Barzolvolimab Significantly Decreases Chronic Spontaneous Urticaria Disease Activity and is Well Tolerated: Top Line Results from a Phase 2 Trial. Journal of Allergy and Clinical Immunology. 153(2). AB366–AB366. 15 indexed citations
3.
Leflein, Jeffrey, Sibylle Haemmerle, K. Lheritier, et al.. (2023). Remibrutinib Improves Chronic Spontaneous Urticaria in Patients Irrespective of Previous Anti-IgE Treatment: Results From a Phase 2b Study. Journal of Allergy and Clinical Immunology. 151(2). AB131–AB131.
4.
5.
6.
7.
Leflein, Jeffrey, et al.. (2008). Long-term Safety and Systemic Effects of Budesonide and Formoterol Administered via One Pressurized Metered-Dose Inhaler (pMDI) in Children With Asthma. Journal of Allergy and Clinical Immunology. 121(2). S155–S155. 4 indexed citations
8.
9.
Åkerlund, Anders, Mats R. Andersson, Jeffrey Leflein, Torben Lildholdt, & Naja Dam Mygind. (2005). Clinical trial design, nasal allergen challenge models, and considerations of relevance to pediatrics, nasal polyposis, and different classes of medication. Journal of Allergy and Clinical Immunology. 115(3). S460–S482. 59 indexed citations
10.
Leflein, Jeffrey, et al.. (2005). Safety features of budesonide inhalation suspension in the long-term treatment of asthma in young children. Advances in Therapy. 22(3). 198–207. 4 indexed citations
11.
Leflein, Jeffrey, Stanley J. Szefler, Kevin R. Murphy, et al.. (2002). Nebulized Budesonide Inhalation Suspension Compared With Cromolyn Sodium Nebulizer Solution for Asthma in Young Children: Results of a Randomized Outcomes Trial. PEDIATRICS. 109(5). 866–872. 59 indexed citations
12.
Leflein, Jeffrey, Sandra M. Gawchik, Stanley P. Galant, et al.. (2002). Safety of budesonide inhalation suspension (Pulmicort Respules) after up to 52 weeks of treatment in infants and young children with persistent asthma.. PubMed. 22(6). 359–66. 12 indexed citations
13.
Mellon, Michael, Jeffrey Leflein, Karen Walton–Bowen, et al.. (2000). Comparable Efficacy of Administration with Face Mask or Mouthpiece of Nebulized Budesonide Inhalation Suspension for Infants and Young Children with Persistent Asthma. American Journal of Respiratory and Critical Care Medicine. 162(2). 593–598. 41 indexed citations
14.
Leflein, Jeffrey, et al.. (2000). 775 Budenosine inhalation suspension (BIS) is more effective than cromolyn sodium (Intal) in controlling asthma over 52 weeks in young children with persistent asthma. Journal of Allergy and Clinical Immunology. 105(1). S261–S261. 3 indexed citations
15.
Leflein, Jeffrey. (2000). Once-daily use of inhaled corticosteroids: A new regimen in the treatment of persistent asthma. Allergology International. 49(1). 7–17. 3 indexed citations
16.
Leflein, Jeffrey, et al.. (1995). Delivery of glucocorticoids by jet nebulization: Aerosol characteristics and output. Journal of Allergy and Clinical Immunology. 95(5). 944–949. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by María Angeles Zambonino Breakdown of academic impact, for papers by R. Ferrenq Dubost Breakdown of academic impact, for papers by Andrea Di Rienzo Businco Breakdown of academic impact, for papers by M. L. Kowalski Breakdown of academic impact, for papers by Claudia Calogero Breakdown of academic impact, for papers by M. Lecasble Breakdown of academic impact, for papers by A Capristo Breakdown of academic impact, for papers by Seçil Kepil Özdemir Breakdown of academic impact, for papers by Chien‐Chia Chuang Breakdown of academic impact, for papers by Ayşegül Akan
Rankless by CCL
2026